uracil has been researched along with Chronic Kidney Diseases in 14 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 7.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| "We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b." | 3.96 | Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. ( Iliescu, EL; Mercan-Stanciu, A; Toma, L, 2020) |
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 3.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| "7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision." | 1.51 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. ( Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| " RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily." | 1.48 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. ( Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018) |
| "We recruited 36 CKD patients with type 2 diabetes." | 1.40 | Effects of alogliptin in chronic kidney disease patients with type 2 diabetes. ( Mugishima, K; Murasawa, T; Ohno, D; Otsuka, T; Otsuka, Y; Sakai, Y; Sumi, Y; Suzuki, A; Tsuruoka, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Londoño, MC | 2 |
| Riveiro-Barciela, M | 1 |
| Ahumada, A | 1 |
| Muñoz-Gómez, R | 1 |
| Roget, M | 1 |
| Devesa-Medina, MJ | 1 |
| Serra, MÁ | 1 |
| Navascués, CA | 1 |
| Baliellas, C | 1 |
| Aldamiz-Echevarría, T | 1 |
| Gutiérrez, ML | 1 |
| Polo-Lorduy, B | 1 |
| Carmona, I | 1 |
| Benlloch, S | 1 |
| Bonet, L | 1 |
| García-Samaniego, J | 1 |
| Jiménez-Pérez, M | 1 |
| Morán-Sánchez, S | 1 |
| Castro, Á | 1 |
| Delgado, M | 1 |
| Gea-Rodríguez, F | 1 |
| Martín-Granizo, I | 1 |
| Montes, ML | 1 |
| Morano, L | 1 |
| Castaño, MA | 1 |
| de Los Santos, I | 1 |
| Laguno, M | 2 |
| Losa, JE | 1 |
| Montero-Alonso, M | 1 |
| Rivero, A | 1 |
| de Álvaro, C | 1 |
| Manzanares, A | 1 |
| Mallolas, J | 2 |
| Barril, G | 1 |
| González-Parra, E | 1 |
| García-Buey, L | 1 |
| Wiegand, J | 1 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 1 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Iliescu, EL | 1 |
| Mercan-Stanciu, A | 1 |
| Toma, L | 1 |
| Sanai, FM | 1 |
| Alghamdi, AS | 1 |
| Afghani, AA | 1 |
| Alswat, K | 1 |
| AlZanbagi, A | 1 |
| Alghamdi, MN | 1 |
| AlMousa, A | 1 |
| Aseeri, M | 1 |
| Assiri, AM | 1 |
| Babatin, MA | 1 |
| Abdel-Razek, W | 1 |
| Waked, I | 1 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Fabrizi, F | 1 |
| Negro, F | 1 |
| Bondin, M | 1 |
| Cacoub, P | 1 |
| Örmeci, N | 1 |
| Sezgin, O | 1 |
| Karaali, R | 1 |
| Aygen, B | 1 |
| Turan, D | 1 |
| Yaras, S | 1 |
| Erdem, İ | 1 |
| Yildiz, O | 1 |
| Karakaya, F | 1 |
| Ateş, K | 1 |
| Asiller, ÖÖ | 1 |
| Charbonnel, B | 1 |
| Schweizer, A | 1 |
| Dejager, S | 1 |
| Nakamura, Y | 1 |
| Inagaki, M | 1 |
| Shimizu, T | 1 |
| Fujita, K | 1 |
| Inoue, M | 1 |
| Gotoh, H | 1 |
| Oguchi, K | 1 |
| Goto, Y | 1 |
| Sakai, Y | 1 |
| Suzuki, A | 1 |
| Mugishima, K | 1 |
| Sumi, Y | 1 |
| Otsuka, Y | 1 |
| Otsuka, T | 1 |
| Ohno, D | 1 |
| Murasawa, T | 1 |
| Tsuruoka, S | 1 |
| Ohashi, N | 1 |
| Tsuji, N | 1 |
| Naito, Y | 1 |
| Iwakura, T | 1 |
| Isobe, S | 1 |
| Ono, M | 1 |
| Fujikura, T | 1 |
| Tsuji, T | 1 |
| Sakao, Y | 1 |
| Yasuda, H | 1 |
| Kato, A | 1 |
| Fujigaki, Y | 1 |
| Uchida, T | 1 |
| Oda, T | 1 |
| Matsubara, H | 1 |
| Watanabe, A | 1 |
| Takechi, H | 1 |
| Oshima, N | 1 |
| Sakurai, Y | 1 |
| Kumagai, H | 1 |
| Flynn, C | 1 |
| Bakris, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uracil and Chronic Kidney Diseases
| Article | Year |
|---|---|
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofur | 2018 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-P | 2013 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2013 |
1 trial available for uracil and Chronic Kidney Diseases
| Article | Year |
|---|---|
Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug-Related Side Effect | 2013 |
10 other studies available for uracil and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Ther | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Thera | 2020 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Ma | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropan | 2019 |
Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypo | 2014 |
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Topics: Aged; Asian People; Body Mass Index; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; | 2014 |
Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis.
Topics: Actins; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Urea Nitrogen; Calci | 2017 |